NCT00210652View on ClinicalTrials.gov

An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
EpilepsyEpilepsies, Partial
Interventions
DRUG

RWJ 333369:

Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor

All Listed Sponsors
lead

SK Life Science, Inc.

INDUSTRY

NCT00210652 - An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy | Biotech Hunter | Biotech Hunter